Systemic Bevacizumab (Avastin) for Juvenile‐Onset Recurrent Respiratory Papillomatosis: A Systematic Review
| Autor: | Emily F. Boss, Jonathan Walsh, David E. Tunkel, Grace R. Leu, Patrick A. Upchurch, Marisa A. Ryan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pediatrics
medicine.medical_specialty Time Factors Bevacizumab Angiogenesis Inhibitors Disease Severity of Illness Index Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Recurrence Secondary Prevention Humans Medicine Disseminated disease Dosing Infusions Intravenous 030223 otorhinolaryngology Adverse effect Respiratory Tract Infections business.industry Papillomavirus Infections medicine.disease Discontinuation Clinical trial Treatment Outcome Otorhinolaryngology 030220 oncology & carcinogenesis Recurrent Respiratory Papillomatosis business medicine.drug |
| Zdroj: | The Laryngoscope. 131:1138-1146 |
| ISSN: | 1531-4995 0023-852X |
| Popis: | OBJECTIVES Juvenile onset recurrent respiratory papillomatosis (JORRP) can cause severe or disseminated disease. Surgical treatment may be inadequate. Systemic bevacizumab has shown initial success for severe JORRP. The objective of this systematic review was to assess usage, effectiveness, and safety of this treatment. METHODS We searched PubMed, Embase, and Web of Science for studies of humans with JORRP treated with systemic bevacizumab. Two researchers independently reviewed the studies to determine inclusion and aggregate data on patient characteristics, dosing protocols, treatment response, adverse events, and level of evidence. RESULTS Of 80 identified articles, 12 studies were included detailing 20 distinct cases. At a mean age of 12.8 years (range = 1-43 years) patients received initial dosing of 5 to 10 mg/kg of bevacizumab followed by ongoing doses at a mean 3-week intervals (range = 2-5 weeks). All patients had clinically significant disease reduction with reduced need for surgery. Six patients (30%) had complete response in at least one involved anatomic site. Eleven (55%) required no surgery after initiating treatment. There was recurrence in all four patients whose treatment was stopped, but had rapid improvement with treatment resumption. Six (30%) experienced mild or moderate adverse events. CONCLUSIONS Marked improvement in severe JORRP has been reported from systemic bevacizumab. Treatment protocols vary, and treatment discontinuation was not feasible in any reported patient. Based on currently available data, systemic bevacizumab can be considered for severe JORRP as it appears to be well tolerated and effective. A clinical trial could enhance the understanding of its safety and efficacy for this indication. Laryngoscope, 131:1138-1146, 2021. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text